Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
2.
J Biomed Mater Res B Appl Biomater ; 108(2): 367-376, 2020 02.
Article in English | MEDLINE | ID: mdl-31033211

ABSTRACT

The in vivo resorption rate of two injectable apatitic calcium phosphate cements used in clinics (Graftys® HBS and NORIAN®) was compared, using a good laboratory practice (GLP) study based on an animal model of critical-sized bone defect. To rationalize the markedly different biological properties observed for both cements, key physical features were investigated, including permeability and water-accessible porosity, total porosity measured by mercury intrusion and gravimetry, and microstructure. Due to a different concept for creating porosity between the two cements investigated in this study, a markedly different microstructural arrangement of apatite crystals was observed in the intergranular space, which was found to significantly influence both the mechanical strength and in vivo degradation of the two calcium phosphate cements.


Subject(s)
Apatites/chemistry , Apatites/metabolism , Bone Cements/chemistry , Bone Cements/metabolism , Tissue Scaffolds/chemistry , Animals , Bone Transplantation , Calcium Carbonate/chemistry , Compressive Strength , Female , Hypromellose Derivatives/chemistry , In Vitro Techniques , Injections , Materials Testing , Microspheres , Permeability , Polysaccharides/chemistry , Porosity , Rabbits , Solubility , Tissue Engineering
3.
J Tissue Eng Regen Med ; 12(2): e854-e866, 2018 02.
Article in English | MEDLINE | ID: mdl-28079305

ABSTRACT

Calcium phosphate (CaP)-based biomaterials are commonly used in bone reconstructive surgery to replace the damaged tissue, and can also serve as vectors for local drug delivery. Due to its inhibitory action on osteoclasts, the semi-metallic element gallium (Ga) is used for the systemic treatment of disorders associated with accelerated bone resorption. As it was demonstrated that Ga could be incorporated in the structure of CaP biomaterials, we investigated the biological properties of Ga-loaded CaP biomaterials. Culturing bone cells on Ga-CaP, we observed a decrease in osteoclast number and a downregulation of late osteoclastic markers expression, while Ga-CaP upregulated the expression of osteoblastic marker genes involved in the maturation of bone matrix. We next investigated in vivo bone reconstructive properties of different Ga-loaded biomaterials using a murine bone defect healing model. All implanted biomaterials showed a good osseointegration into the surrounding host tissue, accompanied by a successful bone ingrowth and bone marrow reconstruction, as evidenced by histological analysis. Moreover, quantitative micro-computed tomography analysis of implants revealed that Ga enhanced total defect filling. Lastly, we took advantage for the first time of a particular mode of non-linear microscopy (second harmonic generation) to quantify in vivo bone tissue reconstruction within a CaP bone substitute. By doing so, we showed that Ga exerted a positive impact on mature organized collagen synthesis. As a whole, our data support the hypothesis that Ga represents an attractive additive to CaP biomaterials for bone reconstructive surgery. Copyright © 2017 John Wiley & Sons, Ltd.


Subject(s)
Biocompatible Materials/pharmacology , Bone Substitutes/pharmacology , Calcium Phosphates/pharmacology , Gallium/pharmacology , Animals , Apatites/pharmacology , Bone Cements/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cell Shape/drug effects , Cells, Cultured , Femur/drug effects , Humans , Osteoblasts/cytology , Osteoblasts/drug effects , Osteoblasts/metabolism , Rats
4.
J Biomed Mater Res B Appl Biomater ; 106(8): 2786-2795, 2018 11.
Article in English | MEDLINE | ID: mdl-29226553

ABSTRACT

An injectable purely apatitic calcium phosphate cement (CPC) was successfully combined to a water-soluble radiopaque agent (i.e., Xenetix® ), to result in an optimized composition that was found to be as satisfactory as poly(methyl methacrylate) (PMMA) formulations used for vertebroplasty, in terms of radiopacity, texture and injectability. For that purpose, the Xenetix dosage in the cement paste was optimized by injection of the radiopaque CPC in human cadaveric vertebrae under classical PMMA vertebroplasty conditions, performed by interventional radiologists familiar with this surgical procedure. When present in the cement paste up to 70 mg I mL-1 , Xenetix did not influence the injectability, cohesion, and setting time of the resulting composite. After hardening of the material, the same observation was made regarding the microstructure, mechanical strength and alpha-tricalcium phosphate to calcium deficient apatite transformation rate. Upon implantation in bone in a small animal model (rat), the biocompatibility of the Xenetix-containing CPC was evidenced. Moreover, an almost quantitative release of the contrast agent was found to occur rapidly, on the basis of in vitro static and dynamic quantitative studies simulating in vivo implantation. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 2786-2795, 2018.


Subject(s)
Apatites , Bone Cements , Contrast Media , Materials Testing , Spine , Vertebroplasty/methods , Animals , Apatites/chemistry , Apatites/pharmacology , Bone Cements/chemistry , Bone Cements/pharmacology , Contrast Media/chemistry , Contrast Media/pharmacology , Humans , Male , Polymethyl Methacrylate/chemistry , Polymethyl Methacrylate/pharmacology , Rats , Rats, Inbred Lew , Spine/diagnostic imaging , Spine/surgery
5.
Acta Biomater ; 62: 328-339, 2017 10 15.
Article in English | MEDLINE | ID: mdl-28864250

ABSTRACT

Two commercial formulations of apatitic calcium phosphate cements (CPCs), Graftys® Quickset (QS) and Graftys® HBS (HBS), similar in composition but with different initial setting time (7 and 15min, respectively), were combined to ovine whole blood. Surprisingly, although a very cohesive paste was obtained after a few minutes, the setting time of the HBS/blood composite dramatically delayed when compared to its QS analogue and the two blood-free references. Using solid state NMR, scanning electron microscopy and high frequency impedance measurements, it was shown that, in the particular case of the HBS/blood composite, formation of a reticulated and porous organic network occurred in the intergranular space, prior to the precipitation of apatite crystals driven by the cement setting process. The resulting microstructure conferred unique biological properties to this material upon implantation in bone defects, since its degradation rate after 4 and 12weeks was more than twice that for the three other CPCs, with a significant replacement by newly formed bone. STATEMENT OF SIGNIFICANCE: A major challenge in the design of bone graft substitutes is the development of injectable, cohesive, resorbable and self-setting calcium phosphate cement (CPC) that enables rapid cell invasion with initial mechanical properties as close as bone ones. Thus, we describe specific conditions in CPC-blood composites where the formation of a 3D clot-like network can interact with the precipitated apatite crystals formed during the cement setting process. The resulting microstructure appears more ductile at short-term and more sensitive to biological degradation which finally promotes new bone formation. This important and original paper reports the design and in-depth chemical and physical characterization of this groundbreaking technology.


Subject(s)
Apatites , Bone Cements , Ceramics , Materials Testing , Osteogenesis/drug effects , Animals , Apatites/chemistry , Apatites/pharmacology , Bone Cements/chemistry , Bone Cements/pharmacology , Ceramics/chemistry , Ceramics/pharmacology , Rabbits
6.
Acta Biomater ; 24: 322-32, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26074157

ABSTRACT

Different possible options were investigated to combine an apatitic calcium phosphate cement with gallium ions, known as bone resorption inhibitors. Gallium can be either chemisorbed onto calcium-deficient apatite or inserted in the structure of ß-tricalcium phosphate, and addition of these gallium-doped components into the cement formulation did not significantly affect the main properties of the biomaterial, in terms of injectability and setting time. Under in vitro conditions, the amount of gallium released from the resulting cement pellets was found to be low, but increased in the presence of osteoclastic cells. When implanted in rabbit bone critical defects, a remodeling process of the gallium-doped implant started and an excellent bone interface was observed. STATEMENT OF SIGNIFICANCE: The integration of drugs and materials is a growing force in the medical industry. The incorporation of pharmaceutical products not only promises to expand the therapeutic scope of biomaterials technology but to design a new generation of true combination products whose therapeutic value stem equally from both the structural attributes of the material and the intrinsic therapy of the drug. In this context, for the first time an injectable calcium phosphate cement containing gallium was designed with properties suitable for practical application as a local delivery system, implantable by minimally invasive surgery. This important and original paper reports the design and in-depth chemical and physical characterization of this groundbreaking technology.


Subject(s)
Apatites/pharmacology , Bone Cements/pharmacology , Bone Resorption/prevention & control , Calcium Phosphates/pharmacology , Gallium/pharmacology , Animals , Apatites/chemistry , Bone Cements/chemistry , Bone Resorption/metabolism , Bone Resorption/pathology , Calcium Phosphates/chemistry , Cell Line , Gallium/chemistry , Mice , Rabbits
7.
Inorg Chem ; 50(17): 8252-60, 2011 Sep 05.
Article in English | MEDLINE | ID: mdl-21793526

ABSTRACT

Addition of a gallium (Ga) precursor in the typical reaction protocols used for the preparation of ß-tricalcium phosphate (ß-TCP) led to novel Ga-doped ß-TCP ceramics with rhombohedral structures (R3c space group). From the refinement of their X-ray diffraction patterns, it was found that the incorporation of Ga in the ß-TCP network occurs by substitution of one of the five calcium (Ca) sites, while occupation of another Ca site decreases in inverse proportion to the Ga content in the structure. The Ga local environment and the modification of the phosphorus environments due to the Ga/Ca substitution in Ga-doped ß-TCP compounds are probed using (31)P and (71)Ga magic-angle spinning NMR. A decrease of the unit cell volume is observed with increasing Ga content, together with improved mechanical properties. Indeed, the compressive strength of these new bioceramics is enhanced in direct proportion of the Ga content, up to a 2.6-fold increase as compared to pure ß-TCP.


Subject(s)
Calcium Phosphates/chemistry , Ceramics/chemistry , Gallium/chemistry , Magnetic Resonance Spectroscopy/standards , Phosphorus Isotopes , Reference Standards
8.
Acta Biomater ; 7(2): 759-70, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20854940

ABSTRACT

Combination of a bisphosphonate (BP) anti-osteoporotic drug, alendronate, with an apatitic calcium phosphate cement does not significantly affect the main properties of the biomaterial, in terms of injectability and setting time, provided that the BP is introduced chemisorbed onto calcium-deficient apatite, one of the components of the cement. In contrast to other modes of introducing the BP into the cement formulation, this mode allows to minimize alendronate release in the cement paste, thus limiting the setting retardant effect of the BP. An original approach based on high frequency impedance measurements is found to be a convenient method for in situ monitoring of the cement setting reaction. The release profile of the drug from a cement block under continuous flow conditions can be well described using a coupled chemistry/transport model, under simulated in vivo conditions. The results show that the released alendronate concentration is expected to be much lower than the cytotoxic concentration.


Subject(s)
Alendronate/pharmacology , Apatites/pharmacology , Bone Cements/pharmacology , Hip Fractures/prevention & control , Osteoporotic Fractures/prevention & control , Adsorption/drug effects , Calcium Phosphates/pharmacology , Dielectric Spectroscopy , Diphosphonates/pharmacology , Hip Fractures/complications , Imidazoles/pharmacology , Magnetic Resonance Spectroscopy , Osteoporotic Fractures/complications , Time Factors , Zoledronic Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...